Page 99 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

78 PART I The Biology and Pathogenesis of Cancer

109. Stefanello D, Morello E, Roccabianca P, et al.: Marginal excision 129. Santos A, Lopes C, Gartner F, et al.: VEGFR-2 expression in
of low-grade spindle cell sarcoma of canine extremities: 35 dogs malignant tumours of the canine mammary gland: a prospective
(1996-2006), Vet Surg 37:461–465, 2008. survival study, Vet Comp Oncol 14:e83–e92, 2016.
VetBooks.ir 110. Seguin B, Besancon MF, McCallan JL, et al.: Recurrence rate, clini- 130. Gregorio H, Raposo T, Queiroga FL, et al.: High COX-2 expression in
cal outcome, and cellular proliferation indices as prognostic indica-
canine mast cell tumours is associated with proliferation, angiogenesis
tors after incomplete surgical excision of cutaneous grade 11 mast
and decreased overall survival, Vet Comp Oncol 15:1382–1392, 2017.
cell tumors: 28 dogs (1994-2002), J Vet Intern Med 20:933–940, 131. Lavalle GE, Bertagnolli AC, Tavares WL, et al.: Cox-2 expression
2006. in canine mammary carcinomas: correlation with angiogenesis and
111. Thompson JJ, Pearl DL, Yager JA, et al.: Canine subcutaneous overall survival, Vet Pathol 46:1275–1280, 2009.
mast cell tumor: characterization and prognostic indices, Vet Pathol 132. Millanta F, Citi S, Della Santa D, et al.: COX-2 expression in
48:156–168, 2011. canine and feline invasive mammary carcinomas: correlation with
112. Phelps HA, Kuntz CA, Milner RJ, et al.: Radical excision with clinicopathological features and prognostic molecular markers,
five-centimeter margins for treatment of feline injection-site sar- Breast Cancer Res Treat 98:115–120, 2006.
comas: 91 cases (1998-2002), J Am Vet Med Assoc 239:97–106, 133. Iussich S, Maniscalco L, Di Sciuva A, et al.: PDGFRs expression in
2011. dogs affected by malignant oral melanomas: correlation with prog-
113. Tuohy JL, Selmic LE, Worley DR, et al.: Outcome following nosis, Vet Comp Oncol 15:462–469, 2017.
curative-intent surgery for oral melanoma in dogs: 70 cases (1998- 134. Araujo MR, Campos LC, Damasceno KA, et al.: HER-2, EGFR,
2011), J Am Vet Med Assoc 245:1266–1273, 2014. Cox-2 and Ki67 expression in lymph node metastasis of canine
114. Donnelly L, Mullin C, Balko J, et al.: Evaluation of histological mammary carcinomas: association with clinical-pathological
grade and histologically tumour-free margins as predictors of local parameters and overall survival, Res Vet Sci 106:121–130, 2016.
recurrence in completely excised canine mast cell tumours, Vet 135. Santos AA, Lopes CC, Ribeiro JR, et al.: Identification of prognos-
Comp Oncol 13:70–76, 2015. tic factors in canine mammary malignant tumours: a multivariable
115. Aparna MSP, Chatra L, Veena KM, et al.: Field cancerization: a survival study, BMC Vet Res 9:1, 2013.
review, Arch Med Health Sci 136–139, 2013. 136. Sunil Kumar BV, Bhardwaj R, Mahajan K, et al.: The overexpres-
116. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in sion of Hsp90B1 is associated with tumorigenesis of canine mam-
oral stratified squamous epithelium; clinical implications of multi- mary glands, Mol Cell Biochem 440:23–31, 2018.
centric origin, Cancer 6:963–968, 1953. 137. Warhol MJ, Hickey WF, Corson JM: Malignant mesothelioma:
117. Davis B, Schwartz M, Duchemin D, et al.: Validation of a mul- ultrastructural distinction from adenocarcinoma, Am J Surg Pathol
tiplexed gene signature assay for diagnosis of canine cancers from 6:307–314, 1982.
formalin-fixed paraffin-embedded tissues, J Vet Intern Med 31:854– 138. Nakahira R, Michishita M, Yoshimura H, et al.: Neuroendo-
863, 2017. crine carcinoma of the mammary gland in a dog, J Comp Pathol
118. Kiupel M, Teske E, Bostock D: Prognostic factors for treated canine 152:188–191, 2015.
malignant lymphoma, Vet Pathol 36:292–300, 1999. 139. Burkhard MJ, Bienzle D: Making sense of lymphoma diagnos-
119. Kravis LD, Vail DM, Kisseberth WC, et al.: Frequency of argyr- tics in small animal patients, Vet Clin North Am Small Anim Pract
ophilic nucleolar organizer regions in fine-needle aspirates and 43:1331–1347, 2013.
biopsy specimens from mast cell tumors in dogs, J Am Vet Med 140. Kiupel M, Smedley RC, Pfent C, et al.: Diagnostic algorithm to
Assoc 209:1418–1420, 1996. differentiate lymphoma from inflammation in feline small intesti-
120. Bundgaard-Andersen K, Flagstad A, Jensen AL, et al.: Correla- nal biopsy samples, Vet Pathol 48:212–222, 2011.
tion between the histopathological diagnosis by AgNOR count 141. Warren A, Center S, McDonough S, et al.: Histopathologic fea-
and AgNOR area in canine mammary tumors, J Vet Intern Med tures, immunophenotyping, clonality, and eubacterial fluorescence
22:1174–1180, 2008. in situ hybridization in cats with lymphocytic cholangitis/cholan-
121. Ramos-Vara JA: Principles and methods of immunohistochemistry, giohepatitis, Vet Pathol 48:627–641, 2011.
Methods Mol Biol 1641:115–128, 2017. 142. Regan RC, Rassnick KM, Balkman CE, et al.: Comparison of first-
122. Ramos-Vara JA, Miller MA: When tissue antigens and antibodies opinion and second-opinion histopathology from dogs and cats
get along: revisiting the technical aspects of immunohistochem- with cancer: 430 cases (2001-2008), Vet Comp Oncol 8:1–10, 2010.
istry—the red, brown, and blue technique, Vet Pathol 51:42–87, 143. Regan RC, Rassnick KM, Malone EK, et al.: A prospective evalua-
2014. tion of the impact of second-opinion histopathology on diagnostic
123. Priest HL, Hume KR, Killick D, et al.: The use, publication and testing, cost and treatment in dogs and cats with cancer, Vet Comp
future directions of immunocytochemistry in veterinary medicine: Oncol 13:106–116, 2015.
a consensus of the Oncology-Pathology Working Group, Vet Comp 144. Abt AB, Abt LG, Olt GJ: The effect of interinstitution anatomic
Oncol 15:868–880, 2017. pathology consultation on patient-care, Arch Pathol Lab Med
124. Madewell BR: Cellular proliferation in tumors: a review of meth- 119:514–517, 1995.
ods, interpretation, and clinical applications, J Vet Intern Med 145. Kronz JD, Westra WH: The role of second opinion pathology in
15:334–340, 2001. the management of lesions of the head and neck, Curr Opin Oto-
125. Bergman PJ, Ogilvie GK, Powers BE: Monoclonal antibody C219 laryngol Head Neck Surg 13:81–84, 2005.
immunohistochemistry against P-glycoprotein: sequential analysis 146. Kronz JD, Westra WH, Epstein JI: Mandatory second opinion sur-
and predictive ability in dogs with lymphoma, J Vet Intern Med gical pathology at a large referral hospital, Cancer 86:2426–2435,
10:354–359, 1996. 1999.
126. Kiupel M, Webster JD, Kaneene JB, et al.: The use of KIT and 147. Aresu L, Martini V, Rossi F, et al.: Canine indolent and aggressive
tryptase expression patterns as prognostic tools for canine cutane- lymphoma: clinical spectrum with histologic correlation, Vet Comp
ous mast cell tumors, Vet Pathol 41:371–377, 2004. Oncol 13:348–362, 2015.
127. Sagartz JE, Bodley WL, Gamblin RM, et al.: p53 tumor suppres- 148. Comazzi S, Aresu L, Marconato L: Transformation of canine lym-
sor protein overexpression in osteogenic tumors of dogs, Vet Pathol phoma/leukemia to more aggressive diseases: anecdotes or reality?
33:213–221, 1996. Front Vet Sci 2:42, 2015.
128. Koenig A, Bianco SR, Fosmire S, et al.: Expression and significance 149. Valli VE, Bienzel D, Meuten DJ: Tumors of the hemolymphatic
of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors system. In Meuten DJ, editor: Tumors in domestic animals, ed 5,
in canine melanoma, Vet Pathol 39:458–472, 2002. Ames, Iowa, 2017, John Wiley & Sons, Inc, pp 203–273.